Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SaLuDo: Lurbinectedin + Doxorubicin vs Doxorubicin in First-line Metastatic Leiomyosarcoma
2022-502975-45-00Phase 3Authorised
- Sponsor
- PharmaMar
- Start
- Dec 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin in leiomyosarcoma (LMS) (2 arms), sponsored by PharmaMar. Primary endpoint: Progression-free survival by independent review committee (PFS by IRC). Planned start Dec 2023; status: authorised.
02
Drugs
lurbinectedin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on 2022-502975-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502975-45-00.